Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 11, 2013, Pages 5291-5298

  Noordeen, Faseeha ^a,b   Vaillant, Andrew ^c   Jilbert, Allison R ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF PERADENIYA   (Sri Lanka)

^c INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; MEMBRANE ANTIGEN; NUCLEIC ACID POLYMER; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ANTIVIRAL ACTIVITY; ARTICLE; DRUG SYNTHESIS; DUCK; DUCK HEPATITIS B VIRUS; HEPATITIS B VIRUS; IN VITRO STUDY; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS GENOME; VIRUS INFECTION; VIRUS INHIBITION;

ANIMALS; ANTIVIRAL AGENTS; CELL SURVIVAL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS, DUCK; HEPATOCYTES; HYDROGEN-ION CONCENTRATION; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; PRIMARY CELL CULTURE; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84885929771     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01003-13     Document Type: Article

References (32)

1. Fattovich G, Bortolotti F, Donato F. 2008. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors. J. Hepatol. 48:335-352.
2. McMahon BJ. 2005. Epidemiology and natural history of hepatitis B. Semin. Liver Dis. 25(Suppl 1):3-8.
3. Marcellin P, Asselah T, Boyer N. 2005. Treatment of chronic hepatitis B. J. Viral Hepat. 12:333-345.
4. Younger HM, Bathgate AJ, Hayes PC. 2004. Nucleoside analogues for the treatment of chronic hepatitis B. Aliment. Pharmacol. Ther. 20:1211-1230.
5. Agrawal S, Tang JY, Brown DM. 1990. Analytical study of phosphorothioate analogues of oligodeoxynucleotides using high-performance liquid chromatography. J. Chromatogr. 509:396-399.
6. Bernstein DI, Goyette N, Cardin R, Kern ER, Boivin G, Ireland J, Juteau JM, Vaillant A. 2008. Amphipathic DNA polymers exhibit antiherpetic activity in vitro and in vivo. Antimicrob. Agents Chemother. 52:2727-2733.
7. Cardin RD, Bravo FJ, Sewell AP, Cummins J, Flamand L, Juteau JM, Bernstein DI, Vaillant A. 2009. Amphipathic DNA polymers exhibit antiviral activity against systemic murine Cytomegalovirus infection. Virol. J. 6:214. doi:10.1186/1743-422X-6-214.
8. Guzman EM, Cheshenko N, Shende V, Keller MJ, Goyette N, Juteau JM, Boivin G, Vaillant A, Herold BC. 2007. Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression. Antivir. Ther. 12:1147-1156.
9. Kocisko DA, Vaillant A, Lee KS, Arnold KM, Bertholet N, Race RE, Olsen EA, Juteau JM, Caughey B. 2006. Potent antiscrapie activities of degenerate phosphorothioate oligonucleotides. Antimicrob. Agents Chemother. 50:1034-1044.
10. Lee AM, Rojek JM, Gundersen A, Stroher U, Juteau JM, Vaillant A, Kunz S. 2008. Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers. Virology 372:107-117.
11. Matsumura T, Hu Z, Kato T, Dreux M, Zhang YY, Imamura M, Hiraga N, Juteau JM, Cosset FL, Chayama K, Vaillant A, Liang TJ. 2009. Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology 137:673-681.
12. Vaillant A, Juteau JM, Lu H, Liu S, Lackman-Smith C, Ptak R, Jiang S. 2006. Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation. Antimicrob. Agents Chemother. 50:1393-1401.
13. Geary RS, Yu RZ, Watanabe T, Henry SP, Hardee GE, Chappell A, Matson J, Sasmor H, Cummins L, Levin AA. 2003. Pharmacokinetics of a tumor necrosis factor-Alpha phosphorothioate 2=-O-(2-methoxyethyl) modified antisense oligonucleotide: Comparison across species. Drug Metab. Dispos. 31:1419-1428.
14. Henry SP, Geary RS, Yu R, Levin AA. 2001. Drug properties of secondgeneration antisense oligonucleotides: How do they measure up to their predecessors? Curr. Opin. Investig. Drugs 2:1444-1449.
15. Raynaud FI, Orr RM, Goddard PM, Lacey HA, Lancashire H, Judson IR, Beck T, Bryan B, Cotter FE. 1997. Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J. Pharmacol. Exp. Ther. 281:420-427.
16. Sewell KL, Geary RS, Baker BF, Glover JM, Mant TG, Yu RZ, Tami JA, Dorr FA. 2002. Phase I trial of ISIS 104838, a 2=-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-Alpha. J. Pharmacol. Exp. Ther. 303:1334-1343.
17. Caughey B, Raymond GJ. 1993. Sulfated polyanion inhibition of scrapieassociated PrP accumulation in cultured cells. J. Virol. 67:643-650.
18. Hosoya M, Balzarini J, Shigeta S, De Clercq E. 1991. Differential inhibitory effects of sulfated polysaccharides and polymers on the replication of various myxoviruses and retroviruses, depending on the composition of the target amino acid sequences of the viral envelope glycoproteins. Antimicrob. Agents Chemother. 35:2515-2520.
19. Leistner CM, Gruen-Bernhard S, Glebe D. 2008. Role of glycosaminoglycans for binding and infection of hepatitis B virus. Cell. Microbiol. 10:122-133.
20. Schulze A, Gripon P, Urban S. 2007. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology 46:1759-1768.
21. Schultz U, Grgacic E, Nassal M. 2004. Duck hepatitis B virus: An invaluable model system for HBV infection. Adv. Virus Res. 63:1-70.
22. Tuttleman JS, Pugh JC, Summers JW. 1986. In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus. J. Virol. 58:17-25.
23. Pugh JC, Di Q, Mason WS, Simmons H. 1995. Susceptibility to duck hepatitis B virus infection is associated with the presence of cell surface receptor sites that efficiently bind viral particles. J. Virol. 69:4814-4822.
24. Tong Y, Tong S, Zhao X, Wang J, Jun J, Park J, Wands J, Li J. 2010. Initiation of duck hepatitis B virus infection requires cleavage by a furinlike protease. J. Virol. 84:4569-4578.
25. Funk A, Mhamdi M, Hohenberg H, Will H, Sirma H. 2006. pHindependent entry and sequential endosomal sorting are major determinants of hepadnaviral infection in primary hepatocytes. Hepatology 44: 685-693.
26. Kanaori K, Yasumura A, Tajima K, Makino K. 2004. 1H NMR study on equilibrium between parallel G-quartet structures. Nucleic Acids Symp. Ser. (Oxf.) 48:233-234.
27. Kanehara H, Mizuguchi M, Tajima K, Kanaori K, Makino K. 1997. Spectroscopic evidence for the formation of four-stranded solution structure of oligodeoxycytidine phosphorothioate. Biochemistry 36:1790-1797.
28. Manzini G, Yathindra N, Xodo LE. 1994. Evidence for intramolecularly folded i-DNA structures in biologically relevant CCC-repeat sequences. Nucleic Acids Res. 22:4634-4640.
29. Jilbert AR, Miller DS, Scougall CA, Turnbull H, Burrell CJ. 1996. Kinetics of duck hepatitis B virus infection following low dose virus inoculation: One virus DNA genome is infectious in neonatal ducks. Virology 226:338-345.
30. Meier P, Scougall CA, Will H, Burrell CJ, Jilbert AR. 2003. A duck hepatitis B virus strain with a knockout mutation in the putative X ORF shows similar infectivity and in vivo growth characteristics to wild-Type virus. Virology 317:291-298.
31. Zhao Q, Ernst JT, Hamilton AD, Debnath AK, Jiang S. 2002. XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41. AIDS Res. Hum. Retroviruses 18:989-997.
32. Noordeen F, Vaillant A, Jilbert AR. 2013. Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo. Antimicrob. Agents Chemother. 57:5299-5306.